标题
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
作者
关键词
-
出版物
Nature Reviews Neurology
Volume 11, Issue 1, Pages 41-55
出版商
Springer Nature
发表日期
2014-12-16
DOI
10.1038/nrneurol.2014.232
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- CSF Apo-E levels associate with cognitive decline and MRI changes
- (2014) Jon B. Toledo et al. ACTA NEUROPATHOLOGICA
- Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls
- (2014) Eduardo Martínez-Morillo et al. ACTA NEUROPATHOLOGICA
- The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?
- (2014) Flora H. Duits et al. Alzheimers & Dementia
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
- (2014) Bruno Dubois et al. LANCET NEUROLOGY
- Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease
- (2014) Lucilla Parnetti et al. MOVEMENT DISORDERS
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease
- (2014) A. M. Fagan et al. Science Translational Medicine
- Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42
- (2014) Sebastian Palmqvist et al. JAMA Neurology
- Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
- (2014) Michael A. Schwarzschild et al. JAMA Neurology
- Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid
- (2013) Heiko Braak et al. ACTA NEUROPATHOLOGICA
- Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
- (2013) Jon B. Toledo et al. ACTA NEUROPATHOLOGICA
- CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease
- (2013) Jon B. Toledo et al. ACTA NEUROPATHOLOGICA
- New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF
- (2013) Ting Yang et al. Alzheimers & Dementia
- A novel BACE inhibitor (PF-05297909): A two-part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta-amyloid in a first-in-human study
- (2013) Joanne Bell et al. Alzheimers & Dementia
- A phase II study of the gamma-secretase inhibitor avagacestat (BMS-708163) in predementia Alzheimer's disease
- (2013) Vlad Coric et al. Alzheimers & Dementia
- Safety, pharmacokinetics and pharmacodynamics of PQ912, the first glutaminyl cyclase (QC) inhibitor to treat Alzheimer's disease, in healthy elderly
- (2013) Ronald Black et al. Alzheimers & Dementia
- The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease
- (2013) Mark Forman et al. Alzheimers & Dementia
- Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF
- (2013) Francois Bernier et al. Alzheimers & Dementia
- CSF biomarker variability in the Alzheimer's Association quality control program
- (2013) Niklas Mattsson et al. Alzheimers & Dementia
- Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid
- (2013) Susan M. Landau et al. ANNALS OF NEUROLOGY
- Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
- (2013) David Devos et al. ANTIOXIDANTS & REDOX SIGNALING
- Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease
- (2013) Jaren W. Landen et al. CLINICAL NEUROPHARMACOLOGY
- CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
- (2013) Joel Ross et al. Current Alzheimer Research
- Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
- (2013) Stephanie JB Vos et al. LANCET NEUROLOGY
- Cerebrospinal fluid biomarkers in Parkinson disease
- (2013) Lucilla Parnetti et al. Nature Reviews Neurology
- Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
- (2013) C. M. Roe et al. NEUROLOGY
- Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
- (2013) S. J. B. Vos et al. NEUROLOGY
- Oxysterols and Parkinson's disease: Evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease
- (2013) Ingemar Björkhem et al. NEUROSCIENCE LETTERS
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
- (2013) Mikko Hölttä et al. PLoS One
- CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
- (2012) Jon B. Toledo et al. ACTA NEUROPATHOLOGICA
- Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects
- (2012) Bruno P. Imbimbo et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- Three-year follow-up on the IVIg for Alzheimer's phase II study
- (2012) Norman Relkin et al. Alzheimers & Dementia
- First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing
- (2012) Robert Lai et al. Alzheimers & Dementia
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults
- (2012) Donata Paternicò et al. Alzheimers & Dementia
- Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium
- (2012) Maria C. Carrillo et al. Alzheimers & Dementia
- Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue
- (2012) Kim A. Bruggink et al. ANALYTICAL BIOCHEMISTRY
- Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
- (2012) Peder Buchhave ARCHIVES OF GENERAL PSYCHIATRY
- Antioxidants for Alzheimer Disease
- (2012) Douglas R. Galasko et al. ARCHIVES OF NEUROLOGY
- Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
- (2012) Sara Hall et al. ARCHIVES OF NEUROLOGY
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update
- (2012) Marta del Campo et al. Biomarkers in Medicine
- Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer’s disease
- (2012) Anne M Fagan et al. Biomarkers in Medicine
- Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies
- (2012) David S. Goldstein et al. BRAIN
- Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
- (2012) Gary Tong et al. CLINICAL DRUG INVESTIGATION
- Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
- (2012) Erik Portelius et al. CURRENT PHARMACEUTICAL DESIGN
- α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
- (2012) Brit Mollenhauer et al. JOURNAL OF NEURAL TRANSMISSION
- Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans
- (2012) Maria L Maccecchini et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Neutralization of Soluble, Synaptotoxic Amyloid Species by Antibodies Is Epitope Specific
- (2012) W. Zago et al. JOURNAL OF NEUROSCIENCE
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
- (2012) T. T. Seppala et al. NEUROLOGY
- Injury markers predict time to dementia in subjects with MCI and amyloid pathology
- (2012) I. A. van Rossum et al. NEUROLOGY
- Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers
- (2012) M. Scholl et al. NEUROLOGY
- Age and diagnostic performance of Alzheimer disease CSF biomarkers
- (2012) N. Mattsson et al. NEUROLOGY
- Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects
- (2012) Brit Mollenhauer et al. NEUROSCIENCE LETTERS
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System
- (2012) Niklas Mattsson et al. PLoS One
- Phosphorylated -Synuclein in Parkinson's Disease
- (2012) Y. Wang et al. Science Translational Medicine
- ACS Chemical Neuroscience Molecule Spotlight on ELND006: Another γ-Secretase Inhibitor Fails in the Clinic
- (2011) Corey R. Hopkins ACS Chemical Neuroscience
- Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease
- (2011) Fuyuki Tateno et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
- (2011) Hugo Vanderstichele et al. Alzheimers & Dementia
- Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology
- (2011) Anne M. Fagan ARCHIVES OF NEUROLOGY
- Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment
- (2011) Suzanne Craft ARCHIVES OF NEUROLOGY
- Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
- (2011) Y. Compta et al. BRAIN
- CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease
- (2011) Peter LeWitt et al. BRAIN RESEARCH
- Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
- (2011) Orestes V. Forlenza et al. BRITISH JOURNAL OF PSYCHIATRY
- γ-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease
- (2011) Alberto Lleo et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden — Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials
- (2011) Maria Isaac et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- A Window into the Heterogeneity of Human Cerebrospinal Fluid AβPeptides
- (2011) Roberta Ghidoni et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
- (2011) Brit Mollenhauer et al. LANCET NEUROLOGY
- Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias
- (2011) Lucilla Parnetti et al. MOVEMENT DISORDERS
- CSF α-synuclein does not differentiate between parkinsonian disorders
- (2011) M.B. Aerts et al. NEUROBIOLOGY OF AGING
- A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
- (2011) S. Salloway et al. NEUROLOGY
- Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility
- (2011) Niklas Mattsson et al. NEUROMOLECULAR MEDICINE
- On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia
- (2011) F. Geser et al. PROGRESS IN NEUROBIOLOGY
- The Parkinson Progression Marker Initiative (PPMI)
- (2011) Kenneth Marek et al. PROGRESS IN NEUROBIOLOGY
- Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease
- (2010) L. Parnetti et al. ACTA NEUROLOGICA SCANDINAVICA
- Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
- (2010) Lon S. Schneider et al. Alzheimers & Dementia
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
- (2010) Min Shi et al. ANNALS OF NEUROLOGY
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
- (2010) Geert De Meyer ARCHIVES OF NEUROLOGY
- YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
- (2010) Rebecca Craig-Schapiro et al. BIOLOGICAL PSYCHIATRY
- Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology
- (2010) Alberto Serrano-Pozo et al. BRAIN
- DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
- (2010) Zhen Hong et al. BRAIN
- Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
- (2010) Annika Thorsell et al. BRAIN RESEARCH
- Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease
- (2010) Eric R. Siemers et al. CLINICAL NEUROPHARMACOLOGY
- γ-Secretase as a Therapeutic Target in Alzheimers Disease
- (2010) Guardia-Laguarta C. et al. CURRENT DRUG TARGETS
- Differential levels of -synuclein, -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease
- (2010) K. Kasuga et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- CSF amyloid- and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
- (2010) G. Alves et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alzheimer's disease: clinical trials and drug development
- (2010) Francesca Mangialasche et al. LANCET NEUROLOGY
- CSF Aβ42and tau in Parkinson's disease with cognitive impairment
- (2010) Thomas J. Montine et al. MOVEMENT DISORDERS
- Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
- (2010) Kaj Blennow et al. Nature Reviews Neurology
- Boosting power for clinical trials using classifiers based on multiple biomarkers
- (2010) Omid Kohannim et al. NEUROBIOLOGY OF AGING
- Integrating ADNI results into Alzheimer's disease drug development programs
- (2010) Jeffrey L. Cummings NEUROBIOLOGY OF AGING
- Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment
- (2010) M. Lorenzi et al. NEUROBIOLOGY OF AGING
- CSF biomarkers predict a more malignant outcome in Alzheimer disease
- (2010) A. K. Wallin et al. NEUROLOGY
- Comparing predictors of conversion and decline in mild cognitive impairment
- (2010) S. M. Landau et al. NEUROLOGY
- Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease
- (2010) T. Tokuda et al. NEUROLOGY
- CSF amyloid 1-42 predicts cognitive decline in Parkinson disease
- (2010) A. Siderowf et al. NEUROLOGY
- A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease
- (2010) Erik Portelius et al. Alzheimers Research & Therapy
- The neuropathologic substrate of Parkinson disease dementia
- (2009) Kurt A. Jellinger ACTA NEUROPATHOLOGICA
- A γ-secretase inhibitor decreases amyloid-β production in the central nervous system
- (2009) Randall J. Bateman et al. ANNALS OF NEUROLOGY
- Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
- (2009) Tero Tapiola et al. ARCHIVES OF NEUROLOGY
- Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid
- (2009) Timo Grimmer et al. BIOLOGICAL PSYCHIATRY
- Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients
- (2009) Agneta Nordberg et al. Current Alzheimer Research
- Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
- (2009) Anne M. Fagan et al. EMBO Molecular Medicine
- Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
- (2009) Kajsa Sämgård et al. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
- Lithium Trial in Alzheimer's Disease
- (2009) Harald Hampel et al. JOURNAL OF CLINICAL PSYCHIATRY
- Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers
- (2009) Piotr Lewczuk et al. JOURNAL OF NEURAL TRANSMISSION
- Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
- (2009) Volker Welge et al. JOURNAL OF NEURAL TRANSMISSION
- CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies
- (2009) A J Mitchell JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Amyloid Reduction by Amyloid- Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease
- (2009) D. M. Wilcock et al. JOURNAL OF NEUROSCIENCE
- A Immunotherapy: Intracerebral Sequestration of A by an Anti-A Monoclonal Antibody 266 with High Affinity to Soluble A
- (2009) K. Yamada et al. JOURNAL OF NEUROSCIENCE
- Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding
- (2009) N. Tolboom et al. JOURNAL OF NUCLEAR MEDICINE
- Relationships between biomarkers in aging and dementia
- (2009) W. J. Jagust et al. NEUROLOGY
- Age, Neuropathology, and Dementia
- (2009) George M. Savva et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease
- (2008) Adam S. Fleisher et al. ARCHIVES OF NEUROLOGY
- Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
- (2008) Lucilla Parnetti et al. BIOLOGICAL PSYCHIATRY
- CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease
- (2008) Moeko Noguchi-Shinohara et al. BRAIN RESEARCH
- The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients
- (2008) J.-M. Lee et al. CLINICAL CHEMISTRY
- Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
- (2008) Brit Mollenhauer et al. EXPERIMENTAL NEUROLOGY
- Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
- (2008) P Edison et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
- (2008) Lars Lannfelt et al. LANCET NEUROLOGY
- Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study
- (2008) P Lewczuk et al. MOLECULAR PSYCHIATRY
- Biochemical markers in persons with preclinical familial Alzheimer disease
- (2008) J. M. Ringman et al. NEUROLOGY
- Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?
- (2008) Annika Öhrfelt et al. NEUROSCIENCE LETTERS
- Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia
- (2007) Sebastiaan Engelborghs et al. NEUROBIOLOGY OF AGING
- PET imaging of amyloid deposition in patients with mild cognitive impairment
- (2007) Anton Forsberg et al. NEUROBIOLOGY OF AGING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search